Valuation: Norda ASA

Market Cap 513M 55.17M 47.26M 44.22M 40.47M 75.96M 5.28B 76.96M 522M 204M 2.65B 207M 203M 8.77B P/E 2023 *
-
P/E 2024 3.26x
Enterprise Value 264M 28.42M 24.34M 22.78M 20.85M 39.13M 2.72B 39.65M 269M 105M 1.37B 107M 104M 4.52B EV / Sales 2023
-1.24x
EV / Sales 2024 0.4x
Free-Float
6.26%
Yield 2023 *
-
Yield 2024 32.5%
1 day+1.53%
6 months+1.53%
Current year-13.60%
Current year 81
Extreme 81
86.4
1 year 81
Extreme 81
100
3 years 41
Extreme 41
100
5 years 41
Extreme 41
100
10 years 8
Extreme 8
100
Manager TitleAgeSince
Chief Executive Officer - 08/04/2013
Director TitleAgeSince
Chairman 54 31/01/2014
Director/Board Member 68 20/06/2013
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.53%-.--%+6.67%+110.73% 47.66M
+1.09%+5.26%+4.52%+23.38% 51.61B
-1.07%+2.82%+465.96%+570.70% 44.89B
+1.47%+9.79%+35.92%+20.21% 42.77B
+1.44%+7.77%+19.38%+84.65% 42.58B
-0.93%-4.33%+16.18%+55.82% 31.82B
+1.32%+7.30%+33.89%+148.53% 17.33B
-0.60%+1.93% - - 16.63B
+0.03%+3.41%+6.55%+29.84% 14.76B
+1.28%+5.41%+82.40%+46.13% 14.09B
Average +0.56%+4.14%+74.61%+121.11% 27.65B
Weighted average by Cap. +0.49%+4.72%+99.56%+141.37%

Financials

2023 2024
Net sales 86.92M 9.34M 8M 7.49M 6.86M 12.87M 894M 13.04M 88.48M 34.51M 449M 35.09M 34.32M 1.49B 372M 39.97M 34.24M 32.04M 29.33M 55.04M 3.82B 55.77M 379M 148M 1.92B 150M 147M 6.35B
Net income 31.17M 3.35M 2.87M 2.69M 2.46M 4.61M 321M 4.68M 31.73M 12.37M 161M 12.58M 12.31M 533M 126M 13.54M 11.6M 10.85M 9.93M 18.64M 1.3B 18.89M 128M 50M 651M 50.84M 49.73M 2.15B
Net Debt -311M -33.46M -28.66M -26.82M -24.55M -46.07M -3.2B -46.68M -317M -124M -1.61B -126M -123M -5.32B -249M -26.75M -22.91M -21.44M -19.62M -36.83M -2.56B -37.32M -253M -98.78M -1.29B -100M -98.25M -4.25B
Logo Norda ASA
Norda ASA, formerly NorDiag ASA, is a Norway-based company active within the biotechnology sector. It develops, manufactures and markets automated solutions (instruments and tests) for sample preparation of bacterial and human DNA from difficult biological samples for use in the fields of infectious diseases, transplantation testing (HLA Typing) and others. The Company’s products include NorDiag Arrow (CE, IVD), which is a compact, automated solution for nucleic acid extractions, as well as NorDiag Bullet, 8 tip config, which is a fully automated sample preparation instrument for molecular diagnostics and can isolate from samples such as urine, swab, faces, sputum and blood. Its distribution products include Molzym GmbH and Co KG, as well as Hain Lifescience GmbH. Its customers are clinical laboratories, hospitals, research institutes, medical diagnostics and healthcare providers. It is operational through offices and laboratories in Norway, Sweden, Austria and the United States.
Employees
1
  1. Stock Market
  2. Stocks
  3. NORD Stock